Lataa...
Tocilizumab treatment in COVID‐19: A single center experience
Tocilizumab (TCZ), a monoclonal antibody against interleukin‐6 (IL‐6), emerged as an alternative treatment for COVID‐19 patients with a risk of cytokine storms recently. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID‐19 infected patients. The demographic, tr...
Tallennettuna:
| Julkaisussa: | J Med Virol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7262125/ https://ncbi.nlm.nih.gov/pubmed/32253759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.25801 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|